MRUS – Merus N.V

Float Short %

2.59

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.09

EPS Last/This Y

-2.37

EPS This/Next Y

0.59

Price

Target Price

Analyst Recom

2.75

Performance Q

-3.92

Relative Volume

Beta

1.19

Ticker: MRUS

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	MRUS	96.93	1.67	0.02	44281
2025-12-29	MRUS	89.73	2.09	0.25	41736
2025-12-30	MRUS	90	2.09	0.37	41736
2025-12-31	MRUS	90	2.09	0.37	41736
2026-01-02	MRUS	90	2.09	0.37	41736
2026-01-05	MRUS	90	2.09	0.37	41736
2026-01-06	MRUS	90	N/A	N/A	0
2026-01-07	MRUS	90	N/A	N/A	0
2026-01-08	MRUS	90	N/A	N/A	0
2026-01-09	MRUS	90	N/A	N/A	0
2026-01-12	MRUS	90	N/A	N/A	0
2026-01-13	MRUS	90	N/A	N/A	0
2026-01-14	MRUS	90	N/A	N/A	0
2026-01-15	MRUS	90	N/A	N/A	0
2026-01-16	MRUS	90	N/A	N/A	0
2026-01-20	MRUS	90	N/A	N/A	0
2026-01-21	MRUS	90	N/A	N/A	0
2026-01-22	MRUS	90	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

6 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	MRUS	96.93	-116.3	1.8	-5.68
2025-12-29	MRUS	90.00	-116.3	30.7	-5.68
2025-12-30	MRUS	90.00	-116.3	1.9	-5.68
2025-12-31	MRUS	90.00	-116.3	1.9	-5.68
2026-01-02	MRUS	90.00	-108.6	1.9	-5.72
2026-01-05	MRUS	90.00	-102.7	1.9	-5.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

6 items 1 of 1

10 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	MRUS	1.12	-7.37	2.59
2025-12-29	MRUS	1.12	-7.38	2.59
2025-12-30	MRUS	3.04	-7.38	2.59
2025-12-31	MRUS	5.63	-7.38	2.59
2026-01-02	MRUS	5.63	-7.38	2.59
2026-01-05	MRUS	5.63	0	2.59
2026-01-06	MRUS	5.63	0	2.59
2026-01-07	MRUS	5.63	0	2.59
2026-01-08	MRUS	5.63	0	2.59
2026-01-09	MRUS	5.63	0	2.59
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

10 items 1 of 1

Last Quarter Act. EPS

-1.23

Avg. EPS Est. Current Quarter

-1.02

Avg. EPS Est. Next Quarter

-1.32

Insider Transactions

5.63

Institutional Transactions

Beta

1.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

7.3

Max Drawdown 5-Year %

-60.4

Target Price

P/E

Forward P/E

PEG

P/S

120.59

P/B

8.81

P/Free Cash Flow

EPS

-5.33

Average EPS Est. Cur. Y

-5.72

EPS Next Y. (Est.)

-5.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-673.31

Relative Volume

Return on Equity vs Sector %

-76.5

Return on Equity vs Industry %

-61.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

1.9

Merus N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

stock quote shares MRUS – Merus N.V Stock Price stock today

news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch MRUS – Merus N.V yahoo finance google finance

stock history MRUS – Merus N.V invest stock market

stock prices MRUS premarket after hours

ticker MRUS fair value insiders trading

QGEN – Qiagen N.V.

Float Short %

Margin Of Safety %

-5

Put/Call OI Ratio

0.78

EPS Next Q Diff

EPS Last/This Y

1.97

EPS This/Next Y

0.29

Price

54.25

Target Price

52.88

Analyst Recom

2.38

Performance Q

11.85

Relative Volume

2.58

Beta

0.66

Ticker: QGEN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	QGEN	45.37	0.94	0.50	20864
2025-12-29	QGEN	45.62	0.94	0.27	20866
2025-12-30	QGEN	45.31	0.93	0.20	21055
2025-12-31	QGEN	44.98	0.91	0.03	21398
2026-01-02	QGEN	45.2	0.89	3.11	21599
2026-01-05	QGEN	46.49	0.90	0.06	21645
2026-01-06	QGEN	47.01	0.90	0.00	21635
2026-01-07	QGEN	47.3	0.90	0.36	21618
2026-01-08	QGEN	48.45	0.88	0.00	22472
2026-01-09	QGEN	48.3	0.74	0.00	38675
2026-01-12	QGEN	47.24	0.85	0.02	23602
2026-01-13	QGEN	47.19	0.83	0.98	23281
2026-01-14	QGEN	47.43	0.83	0.95	23239
2026-01-15	QGEN	48.4	0.86	0.40	23910
2026-01-16	QGEN	47.57	0.85	0.95	24906
2026-01-20	QGEN	55.49	0.79	0.59	21550
2026-01-21	QGEN	55.69	0.81	0.57	23710
2026-01-22	QGEN	54.24	0.78	0.20	24522
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	QGEN	45.37	-2.5	96.5	2.38
2025-12-29	QGEN	45.62	-2.5	101.5	2.38
2025-12-30	QGEN	45.31	-2.5	94.2	2.38
2025-12-31	QGEN	44.97	-2.5	93.4	2.38
2026-01-02	QGEN	45.19	-2.5	101.1	2.38
2026-01-05	QGEN	46.49	-2.5	115.7	2.38
2026-01-06	QGEN	47.00	-2.5	104.8	2.38
2026-01-07	QGEN	47.30	-2.5	101.9	2.38
2026-01-08	QGEN	48.41	-2.7	80.9	2.38
2026-01-09	QGEN	48.29	-2.7	96.1	2.38
2026-01-12	QGEN	47.24	-2.9	84.8	2.38
2026-01-13	QGEN	47.21	-3.2	97.6	2.38
2026-01-14	QGEN	47.43	-3.2	101.1	2.38
2026-01-15	QGEN	48.38	-3.2	110.3	2.38
2026-01-16	QGEN	47.58	-3.4	88.0	2.38
2026-01-20	QGEN	55.50	-3.4	200.1	2.38
2026-01-21	QGEN	55.67	-3.4	100.6	2.38
2026-01-22	QGEN	54.25	-3.4	82.5	2.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	QGEN	0.00	-0.75	3.17
2025-12-29	QGEN	0.00	-0.79	3.17
2025-12-30	QGEN	0.00	-0.79	3.17
2025-12-31	QGEN	0.00	-0.79	3.17
2026-01-02	QGEN	0.00	-0.79	3.17
2026-01-05	QGEN	0.00	-0.73	3.17
2026-01-06	QGEN	0.00	-0.73	3.17
2026-01-07	QGEN	0.00	-0.73	3.17
2026-01-08	QGEN	0.00	-0.73	3.17
2026-01-09	QGEN	0.00	-0.73	3.17
2026-01-12	QGEN	0.00	0	3.16
2026-01-13	QGEN	0.00	0	2.51
2026-01-14	QGEN	0.00	0	2.51
2026-01-15	QGEN	0.00	0	2.51
2026-01-16	QGEN	0.00	0	2.51
2026-01-20	QGEN	0.00	0	2.51
2026-01-21	QGEN	0.00	0	2.51
2026-01-22	QGEN	0.00	0	0
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.61

Avg. EPS Est. Current Quarter

0.59

Avg. EPS Est. Next Quarter

0.61

Insider Transactions

Institutional Transactions

Beta

0.66

Average Sales Estimate Current Quarter

528

Average Sales Estimate Next Quarter

511

Fair Value

51.73

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

17.6

Max Drawdown 5-Year %

-37.4

Target Price

52.88

P/E

27.8

Forward P/E

21.03

PEG

3.16

P/S

5.42

P/B

3.06

P/Free Cash Flow

23.43

EPS

1.95

Average EPS Est. Cur. Y

2.38

EPS Next Y. (Est.)

2.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

19.58

Relative Volume

2.58

Return on Equity vs Sector %

-16.1

Return on Equity vs Industry %

0.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

82.5

Qiagen N.V.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 5700

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

stock quote shares QGEN – Qiagen N.V. Stock Price stock today

news today QGEN – Qiagen N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch QGEN – Qiagen N.V. yahoo finance google finance

stock history QGEN – Qiagen N.V. invest stock market

stock prices QGEN premarket after hours

ticker QGEN fair value insiders trading

ARGX – argenx SE

Float Short %

2.8

Margin Of Safety %

-15

Put/Call OI Ratio

0.67

EPS Next Q Diff

0.64

EPS Last/This Y

0.97

EPS This/Next Y

10.55

Price

827.03

Target Price

1017.53

Analyst Recom

1.29

Performance Q

-0.93

Relative Volume

1.17

Beta

0.38

Ticker: ARGX

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	ARGX	844.93	0.62	1.00	7929
2025-12-29	ARGX	837.15	0.62	0.19	7964
2025-12-30	ARGX	837.15	0.62	1.29	7985
2025-12-31	ARGX	841.71	0.62	0.13	8002
2026-01-02	ARGX	839.95	0.61	1.00	8097
2026-01-05	ARGX	800.24	0.62	0.61	8228
2026-01-06	ARGX	803.31	0.66	2.36	9466
2026-01-07	ARGX	822.82	0.66	0.11	9585
2026-01-08	ARGX	795.21	0.66	4.33	9703
2026-01-09	ARGX	788.09	0.69	0.26	9968
2026-01-12	ARGX	796.49	0.61	0.43	11040
2026-01-13	ARGX	811.18	0.66	0.54	10493
2026-01-14	ARGX	799.33	0.66	0.10	10524
2026-01-15	ARGX	813.26	0.66	0.57	10512
2026-01-16	ARGX	799.96	0.64	1.06	10380
2026-01-20	ARGX	809.47	0.66	2.88	9211
2026-01-21	ARGX	816.75	0.67	0.26	9286
2026-01-22	ARGX	827.09	0.67	0.46	9343
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	ARGX	845.64	602.9	140.3	14.89
2025-12-29	ARGX	836.57	602.9	125.4	14.89
2025-12-30	ARGX	837.91	602.9	118.6	14.89
2025-12-31	ARGX	841.25	602.9	131.3	14.89
2026-01-02	ARGX	840.08	602.9	123.3	14.89
2026-01-05	ARGX	800.24	602.9	54.6	14.89
2026-01-06	ARGX	803.11	602.9	123.8	14.89
2026-01-07	ARGX	822.21	600.2	144.5	14.89
2026-01-08	ARGX	795.34	600.2	77.2	14.89
2026-01-09	ARGX	787.56	600.2	75.9	14.89
2026-01-12	ARGX	796.28	600.2	132.3	14.89
2026-01-13	ARGX	810.68	605.3	193.6	14.89
2026-01-14	ARGX	799.26	605.3	131.3	14.89
2026-01-15	ARGX	813.24	606.6	163.5	14.89
2026-01-16	ARGX	800.13	606.6	133.5	14.89
2026-01-20	ARGX	809.47	606.6	154.3	14.89
2026-01-21	ARGX	816.96	606.6	180.4	14.89
2026-01-22	ARGX	827.03	606.6	120.9	14.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	ARGX	0.00	22.88	3.06
2025-12-29	ARGX	0.00	20.42	3.06
2025-12-30	ARGX	0.00	20.42	3.06
2025-12-31	ARGX	0.00	20.42	3.06
2026-01-02	ARGX	0.00	20.42	3.06
2026-01-05	ARGX	0.00	20.39	3.06
2026-01-06	ARGX	0.00	20.39	3.06
2026-01-07	ARGX	0.00	20.39	3.06
2026-01-08	ARGX	0.00	20.39	3.06
2026-01-09	ARGX	0.00	20.39	3.06
2026-01-12	ARGX	0.00	-1.30	0
2026-01-13	ARGX	0.00	-1.30	2.80
2026-01-14	ARGX	0.00	-1.30	2.80
2026-01-15	ARGX	0.00	-1.30	2.80
2026-01-16	ARGX	0.00	-1.30	2.80
2026-01-20	ARGX	0.00	-0.61	2.80
2026-01-21	ARGX	0.00	-0.61	2.80
2026-01-22	ARGX	0.00	-0.61	2.80
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

5.18

Avg. EPS Est. Current Quarter

5.01

Avg. EPS Est. Next Quarter

5.82

Insider Transactions

Institutional Transactions

-0.61

Beta

0.38

Average Sales Estimate Current Quarter

1098

Average Sales Estimate Next Quarter

1169

Fair Value

705.04

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

11.5

Max Drawdown 5-Year %

-38.2

Target Price

1017.53

P/E

42.04

Forward P/E

26.91

PEG

0.6

P/S

16.72

P/B

8.3

P/Free Cash Flow

95.4

EPS

19.67

Average EPS Est. Cur. Y

14.89

EPS Next Y. (Est.)

25.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.87

Relative Volume

1.17

Return on Equity vs Sector %

-14.7

Return on Equity vs Industry %

1.2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.13

EBIT Estimation

120.9

argenx SE

Sector: Healthcare

Industry: Biotechnology

Employees: 1599

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

stock quote shares ARGX – argenx SE Stock Price stock today

news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025

marketwatch ARGX – argenx SE yahoo finance google finance

stock history ARGX – argenx SE invest stock market

stock prices ARGX premarket after hours

ticker ARGX fair value insiders trading

STLA – Stellantis N.V.

Float Short %

2.37

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

EPS Last/This Y

-1.37

EPS This/Next Y

0.8

Price

9.79

Target Price

11.49

Analyst Recom

2.53

Performance Q

-11.96

Relative Volume

1.29

Beta

1.42

Ticker: STLA

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	STLA	11.05	0.52	0.50	366891
2025-12-29	STLA	11.04	0.51	0.50	365976
2025-12-30	STLA	11.04	0.49	0.55	362119
2025-12-31	STLA	10.89	0.48	0.05	360462
2026-01-02	STLA	11.41	0.49	0.29	360461
2026-01-05	STLA	11.32	0.49	18.10	360171
2026-01-06	STLA	11.1	0.50	0.62	364268
2026-01-07	STLA	10.79	0.50	0.38	364689
2026-01-08	STLA	11.06	0.50	0.78	365755
2026-01-09	STLA	10.92	0.50	0.02	369105
2026-01-12	STLA	10.45	0.44	1.10	399096
2026-01-13	STLA	10.1	0.45	0.62	404149
2026-01-14	STLA	10.19	0.44	0.35	407461
2026-01-15	STLA	10.01	0.44	0.44	408882
2026-01-16	STLA	9.59	0.43	0.40	408800
2026-01-20	STLA	9.36	0.63	1.58	236569
2026-01-21	STLA	9.93	0.66	0.25	244036
2026-01-22	STLA	9.78	0.65	0.35	250338
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	STLA	11.06	-	10527.0	0.81
2025-12-29	STLA	11.05	-	10548.9	0.81
2025-12-30	STLA	11.05	-	10533.3	0.81
2025-12-31	STLA	10.89	-	10450.5	0.81
2026-01-02	STLA	11.41	-	10647.5	0.81
2026-01-05	STLA	11.32	-	10574.6	0.81
2026-01-06	STLA	11.10	-	11517.6	0.81
2026-01-07	STLA	10.79	-	10372.8	0.81
2026-01-08	STLA	11.06	-	10618.1	0.81
2026-01-09	STLA	10.91	-	10410.9	0.81
2026-01-12	STLA	10.46	-	10253.4	0.81
2026-01-13	STLA	10.09	-	10288.0	0.81
2026-01-14	STLA	10.18	-	10462.4	0.81
2026-01-15	STLA	10.02	-	10404.9	0.81
2026-01-16	STLA	9.60	-	10394.3	0.81
2026-01-20	STLA	9.37	-	10422.3	0.81
2026-01-21	STLA	9.91	-	10802.8	0.81
2026-01-22	STLA	9.79	-	10669.7	0.81
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	STLA	0.00	-3.24	2.51
2025-12-29	STLA	0.00	-3.25	2.51
2025-12-30	STLA	0.00	-3.25	2.51
2025-12-31	STLA	0.00	-3.25	2.51
2026-01-02	STLA	0.00	-3.25	2.51
2026-01-05	STLA	0.00	-3.02	2.51
2026-01-06	STLA	0.00	-3.02	2.51
2026-01-07	STLA	0.00	-3.02	2.51
2026-01-08	STLA	0.00	-3.02	2.51
2026-01-09	STLA	0.00	-3.02	2.51
2026-01-12	STLA	0.00	-2.52	2.51
2026-01-13	STLA	0.00	-2.52	2.37
2026-01-14	STLA	0.00	-2.52	2.37
2026-01-15	STLA	0.00	-2.52	2.37
2026-01-16	STLA	0.00	-2.52	2.37
2026-01-20	STLA	0.00	-1.97	2.37
2026-01-21	STLA	0.00	-1.97	2.37
2026-01-22	STLA	0.00	-1.97	2.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.97

Beta

1.42

Average Sales Estimate Current Quarter

35959

Average Sales Estimate Next Quarter

41394

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

66.8

Max Drawdown 5-Year %

-68.8

Target Price

11.49

P/E

Forward P/E

5.5

PEG

P/S

0.18

P/B

0.33

P/Free Cash Flow

EPS

-0.91

Average EPS Est. Cur. Y

0.81

EPS Next Y. (Est.)

1.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1.64

Relative Volume

1.29

Return on Equity vs Sector %

-21.9

Return on Equity vs Industry %

-11.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

10669.7

Stellantis N.V.

Sector: Consumer Cyclical

Industry: Auto Manufacturers

Employees: 248243

Stellantis N.V. engages in the design, engineering, manufacturing, distribution, and sale of automobiles and light commercial vehicles, engines, transmission systems, metallurgical products, mobility services, and production systems worldwide. It provides luxury and premium vehicles; global sport utility vehicles; American and European brand vehicles, as well as parts and accessories. The company also provides contract services; retail and dealer financing services; and leasing and rental services. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, DS, Dodge, FIAT, Jeep, Maserati, Ram, Opel, Lancia, Vauxhall, Peugeot, and Comau brand names through distributors and dealers. Stellantis N.V. was founded in 1899 and is based in Hoofddorp, the Netherlands.

stock quote shares STLA – Stellantis N.V. Stock Price stock today

news today STLA – Stellantis N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch STLA – Stellantis N.V. yahoo finance google finance

stock history STLA – Stellantis N.V. invest stock market

stock prices STLA premarket after hours

ticker STLA fair value insiders trading

PHG – Koninklijke Philips N.V.

Float Short %

0.29

Margin Of Safety %

Put/Call OI Ratio

0.95

EPS Next Q Diff

EPS Last/This Y

-0.02

EPS This/Next Y

0.15

Price

29.74

Target Price

30.75

Analyst Recom

2.32

Performance Q

4.76

Relative Volume

0.78

Beta

0.78

Ticker: PHG

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	PHG	27.11	1.14	1.21	9265
2025-12-29	PHG	27.27	1.13	16.33	9278
2025-12-30	PHG	27.4	1.13	0.18	9283
2025-12-31	PHG	27.08	1.13	3.20	9300
2026-01-02	PHG	27.07	1.13	999.99	9332
2026-01-05	PHG	28.04	1.14	0.05	9362
2026-01-06	PHG	28.7	1.08	0.01	9567
2026-01-07	PHG	29.1	0.97	1.24	10088
2026-01-08	PHG	29.44	0.97	0.21	10106
2026-01-09	PHG	29.55	0.96	0.24	10180
2026-01-12	PHG	29.79	0.97	0.00	10169
2026-01-13	PHG	29.63	0.97	1.23	10188
2026-01-14	PHG	30.08	0.98	0.61	10218
2026-01-15	PHG	30.17	0.97	0.01	10250
2026-01-16	PHG	29.59	0.96	0.22	10286
2026-01-20	PHG	28.51	1.15	2.63	7790
2026-01-21	PHG	29.21	1.15	0.00	7830
2026-01-22	PHG	29.74	0.95	0.29	8593
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	PHG	27.11	-7.0	580.7	1.61
2025-12-29	PHG	27.26	-7.0	588.7	1.61
2025-12-30	PHG	27.38	-7.0	586.5	1.61
2025-12-31	PHG	27.08	-7.0	534.9	1.61
2026-01-02	PHG	27.08	-7.0	539.0	1.61
2026-01-05	PHG	28.04	-7.0	625.4	1.61
2026-01-06	PHG	28.70	-7.0	610.1	1.61
2026-01-07	PHG	29.12	-7.0	632.2	1.61
2026-01-08	PHG	29.44	-7.0	579.5	1.61
2026-01-09	PHG	29.57	-7.0	529.7	1.61
2026-01-12	PHG	29.79	-7.0	532.5	1.61
2026-01-13	PHG	29.64	-7.0	514.3	1.61
2026-01-14	PHG	30.10	-5.6	535.6	1.61
2026-01-15	PHG	30.17	-5.6	533.6	1.61
2026-01-16	PHG	29.58	-5.6	485.8	1.61
2026-01-20	PHG	28.51	-5.6	458.3	1.61
2026-01-21	PHG	29.20	-5.6	567.6	1.61
2026-01-22	PHG	29.74	-5.6	573.5	1.61
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	PHG	0	1.24	0.27
2025-12-29	PHG	0	1.07	0.27
2025-12-30	PHG	0	1.07	0.27
2025-12-31	PHG	0	1.07	0.27
2026-01-02	PHG	0	1.07	0.27
2026-01-05	PHG	0	1.09	0.27
2026-01-06	PHG	0	1.09	0.27
2026-01-07	PHG	0	1.09	0.27
2026-01-08	PHG	0	1.09	0.27
2026-01-09	PHG	0	1.09	0.27
2026-01-12	PHG	0	1.14	0.27
2026-01-13	PHG	0	1.14	0.29
2026-01-14	PHG	0	1.14	0.29
2026-01-15	PHG	0	1.14	0.29
2026-01-16	PHG	0	1.14	0.29
2026-01-20	PHG	0	1.16	0.29
2026-01-21	PHG	0	1.16	0.29
2026-01-22	PHG	0	1.16	0.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.37

Avg. EPS Est. Current Quarter

0.5

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

1.16

Beta

0.78

Average Sales Estimate Current Quarter

5023

Average Sales Estimate Next Quarter

3796

Fair Value

35.05

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

47.5

Max Drawdown 5-Year %

-79.7

Target Price

30.75

P/E

Forward P/E

17.26

PEG

1.62

P/S

1.45

P/B

2.28

P/Free Cash Flow

20.86

EPS

-0.82

Average EPS Est. Cur. Y

1.61

EPS Next Y. (Est.)

1.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3.89

Relative Volume

0.78

Return on Equity vs Sector %

-25.7

Return on Equity vs Industry %

-16.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

573.5

Koninklijke Philips N.V. NY Reg

Sector: Healthcare

Industry: Medical Devices

Employees: 67035

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides diagnostic imaging solutions, includes magnetic resonance imaging; X-ray systems; and computed tomography (CT) systems and software comprising detector-based spectral CT solutions; ultrasound imaging solutions focused on diagnosis, treatment planning and guidance for cardiac, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional X-ray systems and software solutions; and interventional image devices and software to aid in the diagnosis, navigation, treatment, and confirmation in minimally invasive interventional coronary, peripheral vascular, and hearth rhythm management procedures. The company also offers acute patient management solutions; emergency care solutions; patient care management in ambulatory and home care; sleep and respiratory care solutions; and vendor-agnostic software solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental and women's health solutions; and grooming and beauty products and solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

stock quote shares PHG – Koninklijke Philips N.V. Stock Price stock today

news today PHG – Koninklijke Philips N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch PHG – Koninklijke Philips N.V. yahoo finance google finance

stock history PHG – Koninklijke Philips N.V. invest stock market

stock prices PHG premarket after hours

ticker PHG fair value insiders trading

ASML – ASML Holding N.V.

Float Short %

0.3

Margin Of Safety %

-28

Put/Call OI Ratio

1.05

EPS Next Q Diff

-0.55

EPS Last/This Y

2.36

EPS This/Next Y

2.21

Price

1395.22

Target Price

1395.14

Analyst Recom

1.65

Performance Q

36.09

Relative Volume

1.24

Beta

1.87

Ticker: ASML

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	ASML	1071.82	1.14	0.62	149593
2025-12-29	ASML	1065.58	1.14	0.95	139473
2025-12-30	ASML	1071.98	1.14	1.16	142676
2025-12-31	ASML	1070.86	1.14	1.22	145770
2026-01-02	ASML	1164.48	1.14	0.97	148226
2026-01-05	ASML	1224.99	1.12	0.72	145340
2026-01-06	ASML	1242.17	1.13	1.03	155921
2026-01-07	ASML	1228.36	1.14	1.57	161752
2026-01-08	ASML	1194.91	1.16	1.27	165349
2026-01-09	ASML	1274.17	1.15	0.56	171766
2026-01-12	ASML	1281.36	1.15	2.41	166458
2026-01-13	ASML	1272.23	1.24	1.20	179855
2026-01-14	ASML	1263.17	1.25	0.89	185413
2026-01-15	ASML	1330	1.21	1.17	192536
2026-01-16	ASML	1358.81	1.23	0.55	208897
2026-01-20	ASML	1326.47	0.99	0.95	128293
2026-01-21	ASML	1361.44	1.01	0.99	138005
2026-01-22	ASML	1390.86	1.05	0.95	145635
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	ASML	1072.15	10.1	596.2	24.71
2025-12-29	ASML	1066.03	10.1	554.7	24.71
2025-12-30	ASML	1072.53	10.1	605.6	24.71
2025-12-31	ASML	1069.93	10.1	277.0	24.71
2026-01-02	ASML	1163.60	10.1	1424.0	24.71
2026-01-05	ASML	1225.02	10.1	1457.6	24.71
2026-01-06	ASML	1242.31	9.9	401.1	24.71
2026-01-07	ASML	1228.67	10.0	249.0	24.71
2026-01-08	ASML	1195.10	10.0	-107.6	24.71
2026-01-09	ASML	1272.43	10.0	1782.4	24.71
2026-01-12	ASML	1279.54	10.0	953.8	24.71
2026-01-13	ASML	1270.55	9.8	137.5	24.71
2026-01-14	ASML	1263.56	9.8	-135.7	24.71
2026-01-15	ASML	1331.42	10.1	817.4	24.71
2026-01-16	ASML	1360.12	10.1	298.2	24.71
2026-01-20	ASML	1326.11	10.0	-249.8	24.71
2026-01-21	ASML	1360.71	10.0	447.3	24.71
2026-01-22	ASML	1395.22	10.0	617.0	24.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	ASML	0.00	5.20	0.31
2025-12-29	ASML	0.00	5.41	0.31
2025-12-30	ASML	0.00	5.41	0.31
2025-12-31	ASML	0.00	5.41	0.31
2026-01-02	ASML	0.00	5.41	0.31
2026-01-05	ASML	0.00	5.79	0.31
2026-01-06	ASML	0.00	5.79	0.31
2026-01-07	ASML	0.00	5.79	0.31
2026-01-08	ASML	0.00	5.79	0.31
2026-01-09	ASML	0.00	5.79	0.31
2026-01-12	ASML	0.00	6.03	0.31
2026-01-13	ASML	0.00	6.03	0.30
2026-01-14	ASML	0.00	6.03	0.30
2026-01-15	ASML	0.00	6.03	0.30
2026-01-16	ASML	0.00	6.03	0.30
2026-01-20	ASML	0.00	4.93	0.30
2026-01-21	ASML	0.00	4.93	0.30
2026-01-22	ASML	0.00	4.93	0.30
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

6.41

Avg. EPS Est. Current Quarter

7.53

Avg. EPS Est. Next Quarter

5.86

Insider Transactions

Institutional Transactions

4.93

Beta

1.87

Average Sales Estimate Current Quarter

9504

Average Sales Estimate Next Quarter

8057

Fair Value

998.36

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

-1.4

Max Drawdown 5-Year %

-56.9

Target Price

1395.14

P/E

52.23

Forward P/E

43.7

PEG

1.67

P/S

15.22

P/B

24.23

P/Free Cash Flow

55.44

EPS

26.71

Average EPS Est. Cur. Y

24.71

EPS Next Y. (Est.)

26.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

29.36

Relative Volume

1.24

Return on Equity vs Sector %

-2.3

Return on Equity vs Industry %

4.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

617

ASML Holding N.V. - New York Re

Sector: Technology

Industry: Semiconductor Equipment & Materials

Employees: 43461

ASML Holding N.V. provides lithography solutions for the development, production, marketing, sales, upgrading, and servicing of advanced semiconductor equipment systems. It offers lithography, metrology, and inspection systems. The company also provides extreme ultraviolet lithography systems; and deep ultraviolet lithography systems comprising immersion and dry lithography systems solutions to manufacture various range of semiconductor nodes and technologies. In addition, it offers metrology and inspection systems, including YieldStar optical metrology systems to assess the quality of patterns on the wafers; and HMI electron beam solutions to identify and analyze individual chip defects. Further, the company provides computational lithography solutions, and lithography systems and control software solutions; and refurbishes and upgrades lithography systems, as well as offers customer support and related services. Additionally, it offers hardware, software, and services to chipmakers to produce the patterns of integrated circuits. The company operates in Japan, South Korea, Singapore, Taiwan, China, rest of Asia, the Netherlands, rest of Europe, the Middle East, Africa, and the United States. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands.

stock quote shares ASML – ASML Holding N.V. Stock Price stock today

news today ASML – ASML Holding N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch ASML – ASML Holding N.V. yahoo finance google finance

stock history ASML – ASML Holding N.V. invest stock market

stock prices ASML premarket after hours

ticker ASML fair value insiders trading

No more stocks to show

MRUS – Merus N.V

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

QGEN – Qiagen N.V.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: QGEN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y